Research Papers:

SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma

Wei-Tien Tai, Man-Hsin Hung, Pei-Yi Chu, Yao-Li Chen, Li-Ju Chen, Ming-Hsien Tsai, Min-Husan Chen, Chung-Wai Shiau, Yin-Pin Boo and Kuen- Feng Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:22193-22205. https://doi.org/10.18632/oncotarget.7923

Metrics: PDF 1737 views  |   HTML 2250 views  |   ?  


Wei-Tien Tai1,2, Man-Hsin Hung3,4,9, Pei-Yi Chu5,6, Yao-Li Chen7,10, Li-Ju Chen1,2, Ming-Hsien Tsai1,2, Min-Husan Chen1,2, Chung-Wai Shiau8, Yin-Pin Boo1,2, Kuen-Feng Chen1,2

1Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

2National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan

3Division of Meidcal Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

4Program in Molecular Medicine, School of Life Science, National Yang-Ming University, Taipei, Taiwan

5Department of Pathology, Show Chwan Memorial Hospital, Changhua City, Taiwan

6School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

7Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan

8Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan

9School of Medicine, National Yang-Ming University, Taipei, Taiwan

10School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence to:

Kuen-Feng Chen, e-mail: [email protected]

Keywords: PKM2, SHP-1, PTPN6, sorafenib, HCC

Received: August 20, 2015     Accepted: February 23, 2016     Published: March 5, 2016


Pyruvate kinase M2 (PKM2) is known to promote tumourigenesis through dimer formation of p-PKM2Y105. Here, we investigated whether SH2-containing protein tyrosine phosphatase 1 (SHP-1) decreases p-PKM2Y105 expression and, thus, determines the sensitivity of sorafenib through inhibiting the nuclear-related function of PKM2. Immunoprecipitation and immunoblot confirmed the effect of SHP-1 on PKM2Y105 dephosphorylation. Lactate production was assayed in cells and tumor samples to determine whether sorafenib reversed the Warburg effect. Clinical hepatocellular carcinoma (HCC) tumor samples were assessed for PKM2 expression. SHP-1 directly dephosphorylated PKM2 at Y105 and further decreased the proliferative activity of PKM2; similar effects were found in sorafenib-treated HCC cells. PKM2 was also found to determine the sensitivity of targeted drugs, such as sorafenib, brivanib, and sunitinib, by SHP-1 activation. Significant sphere-forming activity was found in HCC cells stably expressing PKM2. Clinical findings suggest that PKM2 acts as a predicting factor of early recurrence in patients with HCC, particularly those without known risk factors (63.6%). SHP-1 dephosphorylates PKM2 at Y105 to inhibit nuclear function of PKM2 and determines the efficacy of targeted drugs. Targeting PKM2 by SHP-1 might provide new therapeutic insights for patients with HCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7923